ArticleAnnals of surgical oncology2025
Oncologic Outcomes of Intraoperative Autologous Blood Transfusion for Major Oncologic Resection.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIntraoperative autologous blood transfusion (IABT) is contraindicated during oncologic resection owing to concern for metastasis. However, there is a paucity of data to substantiate this claim, and the true risk of IABT in patients with cancer remains unknown. PATIENTS AND
methodsWe identified patients who underwent oncologic resection with IABT during 2010-2021 at our institution. The primary outcome was early metastasis. A subgroup analysis of patients who underwent liver transplants for malignancy was conducted using inverse probability of treatment weighting to compare survival between those who received autologous and allogeneic transfusions.
resultsOf 444 patients, the most common diagnoses were hepatocellular carcinoma (235, 52.9%), cholangiocarcinoma (68, 15.3%), and renal cell carcinoma (18, 4.1%). The median volume of autologous blood transfused was 661 mL (interquartile range (IQR) 337-1491 mL). A total of 7 patients (1.6%) experienced distant recurrence within 90 days, and 35 (7.9%) within 1 year. Of the seven patients with early distant recurrence, only one had metastasis not attributable to preoperative factors. In a subgroup analysis of patients undergoing liver transplant for malignancy, 299 patients who received IABT were compared with 107 patients who received allogeneic transfusion. After adjusting for cancer type, age, sex, estimated blood loss, model for end-stage liver disease (MELD) score, stage, and allograft type, IABT was not associated with overall survival (OS) [adjusted hazard ratio (AHR) 1.30 (95% confidence interval (CI) 0.82-2.03), p = 0.241] or recurrence-free survival (RFS) [AHR 1.15 (95% CI 0.77-1.73), p = 0.498].
conclusionsIABT does not appear to be associated with early recurrence in patients undergoing oncologic resection. IABT should be investigated as a possible alternative to massive transfusion of allogeneic blood during oncologic resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.